Journal of Liver Cancer

Recommendation and Guideline

Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association: Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim; J Liver Cancer. 2023;23(2):241-261. Published online July 14, 2023; DOI: https://doi.org/10.17998/jlc.2023.05.22

24,408 Views
442 Downloads
26 Citations

Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established as conventional TACE using Lipiodol in the 1980s. In the 2000s, drug-eluting beads were developed and applied clinically. Currently, TACE is a commonly used non-surgical treatment modality for patients with HCC who are unsuitable for curative treatment. Considering the vital role of TACE in the management of HCC, it is crucial to organize current knowledge and expert opinions regarding patient preparation, procedural techniques, and post-treatment care in TACE, which can enhance therapeutic efficacy and safety. A group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre- and post- procedural patient care.

Citations

Citations to this article as recorded by

Response to the Letter on “Role of ALBI Grade as a Predictive Factor for Long‐Term Mortality in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)”
Kyoung A Ko, Won Sohn
Journal of Gastroenterology and Hepatology.2026; 41(3): 1101. CrossRef
Injectable hyaluronic acid-based hydrogels with carbon dots and an iron complex for embolization
Minyoung Jin, Sanghee Lee, Yuhyeon Na, Hayoon Jeong, Dong-Hyun Kim, Kun Na
Materials Horizons.2026; 13(7): 3474. CrossRef
Advances and Emerging Techniques in Transarterial Chemoembolization for Hepatocellular Carcinoma
Hunter L. Gazda, Phuoc-Hanh D. Le, Ankit Patel, Arjun Jha, Mina S. Makary
Cancers.2026; 18(3): 514. CrossRef
The State of the Art in Combination Locoregional and Systemic Treatment Strategies for Hepatocellular Carcinoma: Recent Advancements and Future Horizons
Farbod Fazlollahi, Arianna D. Carfora, Marshal King, Elizabeth S. Wrasman, Mina S. Makary
Current Oncology.2026; 33(3): 172. CrossRef
Systemically delivered mRNA-LNPs transfect primary and secondary liver tumors
Laura J. Leighton, Yee Jing Gee, Sachithrani U. Madugalle, Maria Victorova, Nissa L. Carrodus, Kim R. Bridle, Sidney A. Howell, Xiaowen Liang, Gregory C. Miller, Chris L.D. McMillan, Danushka K. Wijesundara, David A. Muller, Darrell H.G. Crawford, Timothy
Molecular Therapy Nucleic Acids.2026; 37(3): 102989. CrossRef
Interventional Radiology in the Management of Primary Liver Malignancies
Kausthubh Hegde, Ronald Arellano, Shams Iqbal
Cancers.2026; 18(14): 2283. CrossRef
All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement
Carolina Lanza, Velio Ascenti, Gaetano Valerio Amato, Giuseppe Pellegrino, Sonia Triggiani, Jacopo Tintori, Cristina Intrieri, Salvatore Alessio Angileri, Pierpaolo Biondetti, Serena Carriero, Pierluca Torcia, Anna Maria Ierardi, Gianpaolo Carrafiello
Journal of Clinical Medicine.2025; 14(2): 314. CrossRef
Case report: Transarterial chemoembolization for nasal hemangiosarcoma in a dog
Keunho Kim, Changgyu Lim, Songyi Kim, Hearang Lim, Sang-Hwan Hyun, Byeong-Teck Kang, Dongwoo Chang, Namsoon Lee
Frontiers in Veterinary Science.2025;[Epub] CrossRef
Transarterial Chemoembolization: A Consistent and Continuously Evolving Therapy for Hepatocellular Carcinoma
Amar Mukund, Niraj Kumar, Amol Srivastava, Akhil Baby
Journal of Clinical and Experimental Hepatology.2025; 15(4): 102538. CrossRef
Silibinin-Conjugated Galactose Dendrimers for Targeted Treatment of Hepatocellular Carcinoma
Aqib Iqbal Dar, Vikrantvir Jain, Anu Rani, Anunay James Pulukuri, Joan Castaneda Gonzalez, Anubhav Dhull, Rishi Sharma, Anjali Sharma
ACS Applied Materials & Interfaces.2025; 17(14): 20980. CrossRef
Conventional transcatheter arterial chemoembolization with gelatin spheres for hepatocellular carcinoma: comparison with nonspherical gelatin sponge particles
Dong Il Gwon, Hee Ho Chu, Gun Ha Kim, Jihoon Kim, Byoung Soo Im, Eunbyeol Ko, Jeongyeon Kim, Jin Hyoung Kim, Gi-Young Ko, Hyun-Ki Yoon
European Radiology.2025; 35(9): 5835. CrossRef
Synergistic effects of L-arginine and argininosuccinate synthetase 1 in inducing apoptosis in hepatocellular carcinoma
Jin Sun Kim, Won-Mook Choi, Ha-Il Kim, Sung Won Chung, Jonggi Choi, Danbi Lee, Kang Mo Kim
Journal of Liver Cancer.2025; 25(1): 79. CrossRef
Optimizing Yttrium-90 Radioembolization Dosimetry for Hepatocellular Carcinoma: A Korean Perspective
In Joon Lee, Hyo-Cheol Kim
Korean Journal of Radiology.2025; 26(7): 688. CrossRef
LI-RADS CT/MRI Treatment Response Assessment Update in 2024
Jaeseung Shin, Kyowon Gu, Ji Hye Min
Journal of the Korean Society of Radiology.2025; 86(3): 352. CrossRef
Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma
Brandon M. Meyers, Howard J. Lim, Mayur Brahmania, Dave M. Liu, Vincent C. Tam, Deanna McLeod, Ravi Ramjeesingh, Jennifer J. Knox, Arndt Vogel
Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef
Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial
Yanting Zou, Szu‐Yuan Wu, Wanqin Zhang, Wei Zhang, Xizhong Shen, Xudong Qu, Qunyan Yao
Liver International.2025;[Epub] CrossRef
Expert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteria
Hyun Yang, Soon Sun Kim, Seong Hee Kang, Jieun Kwon, Do Young Kim, Eunju Kim, Hyun Phil Shin, Jeong Il Yu, Jeong-Ju Yoo, Eileen L. Yoon, Sangheun Lee, Young Eun Chon, Janghan Jung, Jaekyung Cheon, Woosun Choi, Seul Ki Han, Ji Eun Han, Moon Haeng Hur, Hyun
Journal of Liver Cancer.2025; 25(2): 160. CrossRef
Post-embolisation syndrome trajectories and predictors in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation: A retrospective study
Myoung Soo Kim
European Journal of Oncology Nursing.2025; 79: 103031. CrossRef
Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis
Manuel Lim, Jongman Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh
Journal of Liver Cancer.2024; 24(1): 102. CrossRef
A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization
Hae Lim Lee, Seok Hwan Kim, Hee Yeon Kim, Sung Won Lee, Myeong Jun Song
Frontiers in Oncology.2024;[Epub] CrossRef
Clinical outcomes of transarterial chemoembolization in Child–Turcotte Pugh class A patients with a single small (≤3 cm) hepatocellular carcinoma
Jungnam Lee, Young‐Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Jung Hwan Yu, Jin‐Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim
Journal of Gastroenterology and Hepatology.2024; 39(9): 1924. CrossRef
Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022
Yuri Cho, Bo Hyun Kim, Young-Suk Lim
Digestive Disease Interventions.2024; 08(03): 169. CrossRef
Radiomics as a tool for prognostic prediction in transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis
Kaige Deng, Tong Chen, Zijian Leng, Fan Yang, Tao Lu, Jingying Cao, Weixuan Pan, Yongchang Zheng
La radiologia medica.2024; 129(8): 1099. CrossRef
Superselective ablative chemo-ethanol embolization for recurrent single hepatocellular carcinoma: a 6-month outcome analysis
Jae Hwan Lee, Kun Yung Kim, Chong-ho Lee, Minuk Kim, Chang Jin Yoon
Journal of Liver Cancer.2024; 24(2): 217. CrossRef
TACE vs. TARE for HCC ≥ 8 cm: A propensity score analysis
Nhan Hien Phan, Ho Jong Chun, Jung Suk Oh, Su Ho Kim, Byung Gil Choi
Abdominal Radiology.2024; 50(3): 1198. CrossRef
Implications of the first edition of the Korean expert consensus-based practice recommendations for transarterial chemoembolization in the management of hepatocellular carcinoma
Jin Wook Chung
Journal of Liver Cancer.2023; 23(2): 235. CrossRef

Original Article

Epidemiologic Changes in Hepatocellular Carcinoma: A 10-year Single Center Experience in Gangneung, Korea: Young Don Kim, Woo Sung Jang, Jang Hoon Kwon, Jong Sam Hong, Gab Jin Cheon; Journal of the Korean Liver Cancer Study Group. 2013;13(2):123-129. Published online September 30, 2013; DOI: https://doi.org/10.17998/jlc.13.2.123

2,129 Views
16 Downloads

Abstract PDF: Background/Aims
Hepatocellular carcinoma (HCC) is common cause of liver related death in Korea, and the importance of alcohol as an etiology of chronic liver disease including cirrhosis is emphasized recently. We investigated the epidemiologic changes of HCC during last 10 years in single tertiary center in Gangneung, Korea.
Methods
We retrospectively reviewed the medical records of admitted patients diagnosed as HCC in year 2002 and 2012 respectively, and their clinical characteristics were compared.
Results
A total of 214 patients were enrolled. Mean age was 60.1 years and 179 (83.6%) was male. Number of patient with cirrhosis was 160 (74.8%) and with viral hepatitis was 164 (74.8%). Chronic hepatitis B (CHB) was the most common cause of HCC patients with liver cirrhosis (61.9%), and alcohol was 14.4%. The possible curative group (by BCLC stage 0 or A) was only 36.4% (n=78), and had not decreased during the study periods (36.3 % vs. 36.6%, P=0.144), and other clinical variables also had no statistical differences.
Conclusions
The clinical characteristics of HCC including clinical stage at the time of diagnosis were not changed over the last 10 year period, and CHB was still the most common etiology of HCC in Gangneung, Korea.

First
Prev
Page of 1
Next
Last

Search